Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Reelin Protein Diagnostic Test for Mental Disorders

Technology #z02081

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
A Reelin diagnostic blood testMental disorders  Biomarker Protein ReelinExtracellular Biomarker Protein Reelin
Categories
Researchers
S. Hossein Fatemi, MD, PhD
Professor, Department of Psychiatry
External Link (neurosci.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection
US Patent 7,682,805
Publications
Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression
Nature, November 2000, Volume 5, Number 6, Pages 654-663
Files and Attachments
Z02081 Term Sheet [PDF]

Reelin Diagnostic Test for Schizophrenia, Autism, Depression, and Bipolar Disorder

The alterations in Reelin levels occur in significantly specific amounts in schizophrenic, autistic, majorly depressed, and bipolar patients. A Reelin diagnostic blood test aids in the diagnoses and differentiation of autism, major depression, bipolar disorder, and schizophrenia. This test also monitors patient medication compliance, which results in a greater likelihood of patient obedience. This diagnostic test allows neuropsychiatrists to make a quick, accurate diagnosis of mental illnesses and behavioral disorders. This means that clinicians are able to start behavior therapy or prescribe medication earlier resulting in improved patient outcomes.

MN-IP Try and Buy
Try
  • 12-18 months. $5,000/6 months.
  • $0 for MN companies or if sponsoring a minimum of $50K in research.
Buy
  • $25,000 Conversion Fee. No additional patent costs.
  • Royalty rate of 3%. 2% for MN companies.
  • Royalty free for the first $1MM in Sales

** View the Term Sheet **
** Contact Raj Udupa for more information. **

Borderline Mental Disorders Detected with Reelin Diagnostic Test

The diagnosis of neuropsychiatric disorders centers on the patient's symptoms and the observational data of clinicians. Examples of some mental disorders are schizophrenia, autism, major depression, and bipolar disorder. Reelin is a secretory glycoprotein required for normal lamination in the brain and is a biomarker for mental disorders. Alterations in the peripheral blood levels of reelin are the foundation for the diagnostic test of neuropsychiatric disorders. This diagnostic test allows neuropsychiatrists to make a quick, accurate diagnosis of mental illnesses and behavioral disorders and clinicians are able to start behavior therapy or prescribe medication earlier resulting in improved patient outcomes. Another advantage of the diagnostic test is that it eliminates some of the stress associated with neuropsychiatric disorder diagnosis. It also removes the difficulty of ruling in or out a neuropsychiatric disorder; the test is invaluable when a patient appears borderline 'normal' or may be borderline for multiple mental disorders, such as major depression and bipolar depression.

Medical Treatment Can Begin Sooner for Schizophrenic, Autistic, Depressed and Bipolar Patients

A Reelin diagnostic blood test aids in the diagnoses and differentiation of autism, major depression, bipolar disorder, and schizophrenia; the basis of the test is the pathology of neuropsychiatric diseases. The alterations in Reelin levels occur in significantly specific amounts in schizophrenic, autistic, majorly depressed, and bipolar patients. Study data demonstrates that altered levels of Reelin correlate with the subjective evaluation of patients with suspected disease. Also, this diagnostic test aids in patient compliance with required medications.

BENEFITS OF THE REELIN PROTEIN DIAGNOSTIC TEST

  • Improved patient care and outcomes through early diagnosis, which influences treatment decisions
  • Quantitative test versus current observatory and subjective assessments
  • Reduces likelihood of misdiagnosis
  • Validates subjective findings
  • Greater likelihood of patient compliance and less patient hospitalization through medication compliance monitoring

Product Details This product includes the detailed protein structure of the biomarker Reelin and also details the mechanism of action of Reelin in the brain.

Phase of Development Proof of the concept has been established. Currently, additional validation studies, mechanistic studies, and preliminary case-control studies are underway and available.